A Rapid and Sensitive Microfluidics-Based Tool for Seroprevalence Immunity Assessment of COVID-19 and Vaccination-Induced Humoral Antibody Response at the Point of Care.
A Rapid and Sensitive Microfluidics-Based Tool for Seroprevalence Immunity Assessment of COVID-19 and Vaccination-Induced Humoral Antibody Response at the Point of Care.
复制标题
DOI：
10.3390/bios12080621
复制
发表时间：
2022-08-10
期刊：
影响因子：
5.4
通讯作者：
McDevitt, John T.
中科院分区：
文献类型：
--
作者：
Rajsri, Kritika Srinivasan;McRae, Michael P.;Simmons, Glennon W.;Christodoulides, Nicolaos J.;Matz, Hanover;Dooley, Helen;Koide, Akiko;Koide, Shohei;McDevitt, John T.
关键词：
截至2022年8月8日，COVID-19的病原体SARS-CoV-2已感染全球超过5. 85亿人，并导致超过642万人死亡。虽然批准的SARS-CoV-2刺突蛋白疫苗在大多数个体中诱导了强有力的血清转化，显著降低了疾病严重程度和住院治疗的风险，但在老年、免疫功能低下的个体和具有某些预先存在的健康状况的患者中观察到较差的应答。此外，很难预测疫苗接种或既往感染对新的病毒变异（VoC）的保护作用。在这种情况下，能够定量循环抗SARS-CoV-2抗体的快速定量护理点（POC）血清学测定将允许临床医生对加强注射的时间做出明智的决定，允许研究人员测量先前免疫和/或感染个体中针对新VoC的交叉反应性抗体的水平，并帮助评估合适的恢复期血浆供体，以及其他应用。利用芯片实验室生态系统，我们提出了概念验证，优化和POC策略的验证，以量化COVID-19体液保护。该平台涵盖了疾病的整个诊断时间轴、血清转化和疫苗接种反应，涵盖了单次POC检测中的多剂免疫接种。我们的研究结果表明，该平台是快速（约15分钟）和定量的SARS-CoV-2特异性IgG检测。
As of 8 August 2022, SARS-CoV-2, the causative agent of COVID-19, has infected over 585 million people and resulted in more than 6.42 million deaths worldwide. While approved SARS-CoV-2 spike (S) protein-based vaccines induce robust seroconversion in most individuals, dramatically reducing disease severity and the risk of hospitalization, poorer responses are observed in aged, immunocompromised individuals and patients with certain pre-existing health conditions. Further, it is difficult to predict the protection conferred through vaccination or previous infection against new viral variants of concern (VoC) as they emerge. In this context, a rapid quantitative point-of-care (POC) serological assay able to quantify circulating anti-SARS-CoV-2 antibodies would allow clinicians to make informed decisions on the timing of booster shots, permit researchers to measure the level of cross-reactive antibody against new VoC in a previously immunized and/or infected individual, and help assess appropriate convalescent plasma donors, among other applications. Utilizing a lab-on-a-chip ecosystem, we present proof of concept, optimization, and validation of a POC strategy to quantitate COVID-19 humoral protection. This platform covers the entire diagnostic timeline of the disease, seroconversion, and vaccination response spanning multiple doses of immunization in a single POC test. Our results demonstrate that this platform is rapid (~15 min) and quantitative for SARS-CoV-2-specific IgG detection.
登录
查看更多内容
影响因子：
24.8
作者：
Bates TA;McBride SK;Leier HC;Guzman G;Lyski ZL;Schoen D;Winders B;Lee JY;Lee DX;Messer WB;Curlin ME;Tafesse FG
通讯作者：
Tafesse FG
DOI：
10.1073/pnas.2014739117
发表时间：
2020-09-15
影响因子：
11.1
作者：
Ganguli A;Mostafa A;Berger J;Aydin MY;Sun F;Ramirez SAS;Valera E;Cunningham BT;King WP;Bashir R
通讯作者：
Bashir R
影响因子：
82.9
作者：
Ebinger JE;Fert-Bober J;Printsev I;Wu M;Sun N;Prostko JC;Frias EC;Stewart JL;Van Eyk JE;Braun JG;Cheng S;Sobhani K
通讯作者：
Sobhani K
可编程生物 - 纳米芯平台：具有学习能力的即时生物传感器系统。
影响因子：
18.3
作者：
McRae MP;Simmons G;Wong J;McDevitt JT
通讯作者：
McDevitt JT
DOI：
10.1056/nejmoa2119451
发表时间：
2022-04-21
期刊：
The New England journal of medicine
影响因子：
--
作者：
Andrews N;Stowe J;Kirsebom F;Toffa S;Rickeard T;Gallagher E;Gower C;Kall M;Groves N;O'Connell AM;Simons D;Blomquist PB;Zaidi A;Nash S;Iwani Binti Abdul Aziz N;Thelwall S;Dabrera G;Myers R;Amirthalingam G;Gharbia S;Barrett JC;Elson R;Ladhani SN;Ferguson N;Zambon M;Campbell CNJ;Brown K;Hopkins S;Chand M;Ramsay M;Lopez Bernal J
通讯作者：
Lopez Bernal J